EMA Updates Brexit Guidance
On Dec. 1, 2017, the European Medicines Agency (EMA) and the European Commission published updated guidance for pharmaceutical companies regarding the United Kingdom’s withdrawal from the European Union. The new guidance answers additional questions about marketing applications and authorizations.
New in this update is more information on batch release sites located in the UK, which must be located in the EU; the effect on herbal medicinal products; and applications for orphan drug designation. The guidance also discusses the local representatives in the UK mentioned in product information, global marketing, and the sunset clause.
Source: EMA
|
|---|
|
Columnists
 |
Ingredients Insider Cynthia ChallenerEfficiency Demands Drive Advances in API Labs |
 |
Regulatory Watch Jill Wechsler FDA Clarifies Worldwide Inspection Policies |
 |
EU Regulatory Watch Sean Milmo Curbing Drug Shortages in Europe |
Webcasts
Outsourcing
Cambrex Development Center in North Carolina Focuses on Continuous Flow
Cambrex will create a new center of excellence for API process development and clinical supply at its High Point, NC facility and expand its API manufacturing facility in Italy.
Lonza Opens Monoplant for Clovis Oncology’s Rubraca
Clovis Oncology and Lonza celebrated the grand opening of a dedicated production train at Lonza’s Visp, Switzerland site for manufacturing Rubraca (rucaparib).
Outsourcing Development: Small-Scale to Commercial
Industry experts discuss the formulation and development issues that should be considered when addressing scale up from small-scale batches to commercial production.
Sponsored Links
